Wenbin Jiang - Feb 20, 2024 Form 4 Insider Report for Cytek Biosciences, Inc. (CTKB)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Valerie Barnett, Attorney-in-Fact
Stock symbol
CTKB
Transactions as of
Feb 20, 2024
Transactions value $
-$16,794
Form type
4
Date filed
2/22/2024, 05:46 PM
Previous filing
Nov 21, 2023
Next filing
Mar 8, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTKB Common Stock Options Exercise +6.76K +0.13% 5.29M Feb 20, 2024 Direct F1
transaction CTKB Common Stock Tax liability -$16.8K -2K -0.04% $8.38 5.29M Feb 20, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTKB Restricted Stock Units Options Exercise $0 -6.76K -11.54% $0.00 51.8K Feb 20, 2024 Common Stock 6.76K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F2 Represents the number of shares withheld by and surrendered to the Issuer on February 20, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.
F3 The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18.